Allogene Therapeutics, Inc. (ALLO) Ownership
ALLO ownership summary
as of October 17, 2026- Institutions
- 82.7% of shares outstanding
- Insiders
- 11.03% of shares outstanding
- Shares outstanding
- 345.5M
- Float
- 281.1M shares available to trade
- Short interest
- 17.81% 55.6M shares short
- Days to cover
- 9.71 short interest down 6.7% vs prior month
- Institutions 82.73%
- Insiders 11.03%
- Other investors 6.24%
ALLO top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | BlackRock Inc | 8.73% | 30.1M | $39.5M | +11.1M (+57.9%) | June 30, 2026 |
| 2 | Frazier Life Sciences Management, L.P. | 6.50% | 22.4M | $29.4M | +18.6M (+491.2%) | June 30, 2026 |
| 3 | Pfizer Inc | 6.38% | 22.0M | $28.9M | — | June 30, 2026 |
| 4 | State Street Corp | 5.51% | 19.0M | $24.9M | +10.4M (+119.7%) | June 30, 2026 |
| 5 | TPG GP A, LLC | 5.42% | 18.7M | $24.5M | — | June 30, 2026 |
| 6 | Sio Capital Management, LLC | 3.86% | 13.3M | $17.5M | +13.3M (0.0%) | June 30, 2026 |
| 7 | PRIMECAP Management Company | 3.80% | 13.1M | $17.2M | +4.7M (+56.6%) | June 30, 2026 |
| 8 | Vanguard Capital Management, LLC | 3.52% | 12.2M | $15.9M | +5.2M (+75.8%) | June 30, 2026 |
| 9 | FMR Inc | 3.48% | 12.0M | $15.7M | +10.4M (+655.4%) | June 30, 2026 |
| 10 | Citadel Advisors Llc | 2.92% | 10.1M | $13.2M | +3.3M (+48.5%) | June 30, 2026 |
| 11 | Two Sigma Investments LLC | 2.25% | 7.8M | $10.2M | +2.4M (+44.8%) | June 30, 2026 |
| 12 | Geode Capital Management, LLC | 2.04% | 7.0M | $9.2M | +2.9M (+70.9%) | June 30, 2026 |
| 13 | The Goldman Sachs Group Inc | 1.78% | 6.1M | $8.1M | +3.4M (+122.3%) | June 30, 2026 |
| 14 | GordonMD Global Investments LP | 1.53% | 5.3M | $6.9M | +3.9M (+270.5%) | June 30, 2026 |
| 15 | Marshall Wace Asset Management Ltd | 1.47% | 5.1M | $6.7M | +1.6M (+47.8%) | June 30, 2026 |
| 16 | Patient Square Capital LP | 1.46% | 5.0M | $6.6M | +1.6M (+46.4%) | June 30, 2026 |
| 17 | Aberdeen Group PLC | 1.45% | 5.0M | $6.6M | +3.5M (+242.1%) | June 30, 2026 |
| 18 | Millennium Management LLC | 1.40% | 4.8M | $6.3M | +1.5M (+45.8%) | June 30, 2026 |
| 19 | D. E. Shaw & Co LP | 1.36% | 4.7M | $6.2M | +1.9M (+70.4%) | June 30, 2026 |
| 20 | T. Rowe Price Associates, Inc. | 1.34% | 4.6M | $6.1M | −741,619 (−13.8%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 17 holders added 99.9M shares and 1 cut 742K.
ALLO top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Select Biotechnology | 2.91% | 10.0M | $13.2M | −302,000 (−2.9%) | August 31, 2026 |
| 2 | Vanguard Capital Opportunity Inv | 2.72% | 9.4M | $12.3M | +4.0M (+75.0%) | June 30, 2026 |
| 3 | State Street® SPDR® S&P® Biotech ETF | 2.70% | 9.3M | $12.2M | −178,100 (−1.9%) | September 30, 2026 |
| 4 | Vanguard MStar Total Stk Mkt Idx Invest | 2.51% | 8.7M | $11.4M | — | August 31, 2026 |
| 5 | iShares Russell 2000 ETF | 2.01% | 7.0M | $9.1M | −80,128 (−1.1%) | September 30, 2026 |
| 6 | PRIMECAP Odyssey Aggressive Growth | 1.01% | 3.5M | $4.6M | +700,000 (+25.2%) | June 30, 2026 |
| 7 | T. Rowe Price Health Sciences | 1.00% | 3.4M | $4.5M | — | August 31, 2026 |
| 8 | Belfius Equities Cure C Cap | 0.87% | 3.0M | $3.9M | −1.3M (−30.7%) | March 31, 2026 |
| 9 | abrdn Life Sciences Investors | 0.85% | 2.9M | $3.9M | −159,421 (−5.1%) | August 31, 2026 |
| 10 | Fidelity Small Cap Index | 0.84% | 2.9M | $3.8M | +23,323 (+0.8%) | July 31, 2026 |
| 11 | iShares Russell 2000 Value ETF | 0.72% | 2.5M | $3.3M | +3,778 (+0.2%) | September 30, 2026 |
| 12 | Fidelity Enhanced Small Cap Core ETF | 0.60% | 2.1M | $2.7M | +4,371 (+0.2%) | September 30, 2026 |
| 13 | abrdn Healthcare Investors | 0.56% | 1.9M | $2.5M | −323,479 (−14.3%) | August 31, 2026 |
| 14 | BGF World Healthscience A2 | 0.56% | 1.9M | $2.5M | −461,515 (−19.4%) | June 30, 2026 |
| 15 | iShares Biotechnology ETF | 0.54% | 1.9M | $2.4M | −14,120 (−0.8%) | September 30, 2026 |
| 16 | Columbia Small Cap Value Discv A | 0.52% | 1.8M | $2.4M | +11,400 (+0.6%) | August 31, 2026 |
| 17 | BlackRock Advantage Small Cap Core Instl | 0.51% | 1.8M | $2.3M | — | August 31, 2026 |
| 18 | Vanguard Russell 2000 ETF | 0.44% | 1.5M | $2.0M | +35,118 (+2.4%) | August 31, 2026 |
| 19 | Schwab US Small-Cap ETF™ | 0.41% | 1.4M | $1.9M | +954 (+0.1%) | September 30, 2026 |
| 20 | Fidelity Extended Market Index | 0.41% | 1.4M | $1.9M | −32,294 (−2.2%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
ALLO insider transactions
latest 13| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-21 | Annie Yoshiyama | Sell | $2.31 | 9,586 | $22,144 |
| 2026-03-31 | Benjamin Machinas Beneski | Sell | $2.50 | 2,867 | $7,168 |
| 2026-03-16 | Benjamin Machinas Beneski | Sell | $2.47 | 4,835 | $11,942 |
| 2026-03-16 | David D Chang | Sell | $2.47 | 47,763 | $117,975 |
| 2026-03-02 | Benjamin Machinas Beneski | Sell | $2.60 | 7,132 | $18,543 |
| 2026-02-02 | Annie Yoshiyama | Sell | $1.72 | 4,167 | $7,167 |
| 2026-02-02 | Benjamin Machinas Beneski | Sell | $1.73 | 7,549 | $13,060 |
| 2026-02-02 | David D Chang | Sell | $1.80 | 95,269 | $171,484 |
| 2026-02-02 | Earl Martin Douglas | Sell | $1.76 | 22,900 | $40,304 |
| 2026-02-02 | Geoffrey M Parker | Sell | $1.76 | 24,001 | $42,242 |
| 2026-02-02 | Zachary Roberts | Sell | $1.77 | 35,700 | $63,189 |
| 2026-01-21 | Zachary Roberts | Sell | $1.56 | 26,269 | $40,980 |
| 2025-10-21 | Geoffrey M Parker | Sell | $1.26 | 36,744 | $46,297 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
ALLO shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns ALLO
Institutional investors own 82.7% of Allogene Therapeutics's shares and insiders 11.03%. The largest holder is BlackRock Inc with 8.73% of the shares (30.1M), as of June 30, 2026. Among the top 20 institutions, 17 added shares and 1 reduced their stake in the latest filings. Short interest is 17.81% of the float, or 9.71 days of average trading volume. The share count rose 401.3% since 2017.
Related: ALLO analyst forecast, ALLO key metrics. See the ALLO stock overview for the latest quote and news.
ALLO ownership FAQ
Who owns the most Allogene Therapeutics stock?
The largest shareholders of Allogene Therapeutics are BlackRock Inc (8.73%), Frazier Life Sciences Management, L.P. (6.50%), Pfizer Inc (6.38%), State Street Corp (5.51%), TPG GP A, LLC (5.42%).
What percentage of Allogene Therapeutics is owned by institutions?
Institutions hold 82.7% of Allogene Therapeutics's shares outstanding; insiders hold 11.03%.
Which funds own Allogene Therapeutics?
The largest fund holders of Allogene Therapeutics are Fidelity Select Biotechnology (2.91%), Vanguard Capital Opportunity Inv (2.72%), State Street® SPDR® S&P® Biotech ETF (2.70%), Vanguard MStar Total Stk Mkt Idx Invest (2.51%), iShares Russell 2000 ETF (2.01%).
What is Allogene Therapeutics's short interest?
55.6M shares of Allogene Therapeutics were sold short, 17.81% of the float; at the average daily volume it would take 9.71 days to cover.
Are insiders buying or selling Allogene Therapeutics?
Of the latest 13 reported insider transactions in Allogene Therapeutics (since October 21, 2025), 0 were purchases and 13 were sales.
How many shares of Allogene Therapeutics are outstanding?
Allogene Therapeutics has 345.5M shares outstanding, of which 281.1M are in the public float.